Stock comparison
Halozyme Therapeutics
Harrow Health
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
HROW
Harrow Health
Market cap
$1.23B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | HROW | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 54C | HALO |
| Benjamin Graham | 83A | 73D | HALO |
| Philip Fisher | 65B | 65C | Tie |
| Peter Lynch | 53D | 75C | HROW |
| Joel Greenblatt | 40D | 47D | HROW |
| Charlie Munger | 80C | 55D | HALO |
| Terry Smith | 84A | 49D | HALO |
Side-by-side metrics
| Metric | HALO | HROW |
|---|---|---|
| Market cap | $8.1B | $1.23B |
| P/E (TTM) | 24.0x | - |
| EV/EBIT | 10.2x | 35.2x |
| ROIC (TTM) | 23.65% | 8.55% |
| Gross margin | 81.24% | 74.11% |
| Net margin | 23.13% | -5.57% |
| Revenue CAGR 5y | 33.23% | 39.22% |
| EPS CAGR 5y | -1.98% | - |
| Debt / Equity | 1.0x | 10.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Net margin23.13%vs -5.57%+124%
- Debt / Equity1.0xvs 10.5x+91%
- Market cap$8.1Bvs $1.23B+85%
- EV/EBIT10.2xvs 35.2x+71%
HROW leads on
- P/E (TTM)-vs 24.0x+131%
- Revenue CAGR 5y39.22%vs 33.23%+15%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.